Dengue vaccine safety signal: Immune enhancement, waning immunity, or chance occurrence?

Highlights • Dengue vaccine was associated with increased risk of hospitalization during year 3 for young children in Asia. • Currently published data cannot distinguish between immune enhancement, waning immunity, or chance occurrence. • Taken as a whole, data are most consistent with waning immuni...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2017-06, Vol.35 (27), p.3452-3456
Hauptverfasser:	Gessner, Bradford D, Halsey, Neal
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adverse events following immunization Age Age groups Allergy and Immunology Child Child, Preschool Children Clinical trial Clinical trials Data points Dengue Dengue - epidemiology Dengue - prevention & control Dengue fever Dengue Vaccines - adverse effects Dengue Vaccines - immunology Disease control Enrollments Female Follow-Up Studies Hospitalization Humans Hypotheses Immunity Immunity (Disease) Immunization Immunology Incidence Infections Male Population Safety Statistical analysis Tropical diseases Vaccine Vaccines Vector-borne diseases Viral diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Dengue vaccine was associated with increased risk of hospitalization during year 3 for young children in Asia. • Currently published data cannot distinguish between immune enhancement, waning immunity, or chance occurrence. • Taken as a whole, data are most consistent with waning immunity or chance occurrence. • This analysis supports appropriateness of countries using vaccine in endemic areas. • Currently published data do not support a need to determine baseline serostatus before immunizing persons.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2017.05.003